SANTA ANA, Calif., April 15, 2021 (GLOBE NEWSWIRE) — NKGen Biotech, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, today announced that it has appointed Steven Cha, M.D. as its Chief Medical Officer. Dr. Cha will oversee the clinical development of NKGen Biotech's lead product SNK01 as well as its pipeline of other novel NK cell therapies.
“We are extremely pleased to have Steven join the NKGen Biotech team during this rapid growth phase for the Company,” said Stephen Chen, Chief Operating Officer. “His broad expertise and leadership in oncology, early and late-stage drug development, and proficiency with business development transactions make him an ideal fit for NKGen Biotech,” he concluded.
Dr. Cha has 15 years of R&D industry experience encompassing both large and small pharmaceutical companies. Since 2018 he has served as Vice President of Oncology at Samumed LLC, a privately held clinical-stage biotechnology company. Prior …
Full story available on Benzinga.com